CH667994A5 - Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen. - Google Patents

Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen. Download PDF

Info

Publication number: CH667994A5
Authority: CH; Switzerland
Prior art keywords: pharmaceutical compositions; compositions according; somatostatin; administration; sms
Prior art date: 1986-05-27

Application number

CH2138/86A

Other languages

German (de)

English (en)

Inventor

Jacky Vonderscher

Joachim Dr Franz

Michel Dr Steiger

Karl Dr Hornung

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-27

Filing date

1986-05-27

Publication date

1988-11-30

1986-05-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1986-05-27 Priority to CH2138/86A priority Critical patent/CH667994A5/de

1987-05-13 Priority to HU872150A priority patent/HU198626B/hu

1987-05-13 Priority to NL8701143A priority patent/NL8701143A/nl

1987-05-16 Priority to DE19873716437 priority patent/DE3716437A1/de

1987-05-22 Priority to PCT/CH1987/000056 priority patent/WO1987007149A1/de

1987-05-22 Priority to GB8712193A priority patent/GB2190838B/en

1987-05-25 Priority to FI872313A priority patent/FI872313L/fi

1987-05-25 Priority to NO872174A priority patent/NO171484C/no

1987-05-25 Priority to CA000537928A priority patent/CA1299495C/en

1987-05-25 Priority to AU73364/87A priority patent/AU601740B2/en

1987-05-25 Priority to NZ220418A priority patent/NZ220418A/xx

1987-05-25 Priority to PT84943A priority patent/PT84943B/pt

1987-05-25 Priority to GR870820A priority patent/GR870820B/el

1987-05-25 Priority to SE8702188A priority patent/SE8702188L/

1987-05-25 Priority to BE8700598A priority patent/BE1000722A4/fr

1987-05-25 Priority to DK265587A priority patent/DK265587A/da

1987-05-25 Priority to MYPI87000714A priority patent/MY101233A/en

1987-05-25 Priority to IT8747977A priority patent/IT1216814B/it

1987-05-25 Priority to FR878707368A priority patent/FR2599254B1/fr

1987-05-25 Priority to IL82645A priority patent/IL82645A0/xx

1987-05-26 Priority to LU86901A priority patent/LU86901A1/fr

1987-05-26 Priority to KR870005303A priority patent/KR870010870A/ko

1987-05-26 Priority to JP62129572A priority patent/JPS62283930A/ja

1987-05-27 Priority to ES8701555A priority patent/ES2008126A6/es

1987-05-27 Priority to ZA873841A priority patent/ZA873841B/xx

1988-05-22 Priority to CH165/88A priority patent/CH669909A5/de

1988-11-30 Publication of CH667994A5 publication Critical patent/CH667994A5/de

1989-06-14 Priority to FR8907995A priority patent/FR2630916B1/fr

1993-01-25 Priority to US08/008,383 priority patent/US5393738A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
229920001184 polypeptide Polymers 0.000 claims abstract description 20
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 16
210000002381 plasma Anatomy 0.000 claims abstract description 14
150000002772 monosaccharides Chemical class 0.000 claims abstract description 13
150000005846 sugar alcohols Chemical class 0.000 claims abstract description 12
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 9
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 9
230000002496 gastric effect Effects 0.000 claims abstract description 7
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 24
239000008194 pharmaceutical composition Substances 0.000 claims description 23
239000004480 active ingredient Substances 0.000 claims description 22
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 17
239000008103 glucose Substances 0.000 claims description 17
102000005157 Somatostatin Human genes 0.000 claims description 12
108010056088 Somatostatin Proteins 0.000 claims description 12
150000002170 ethers Chemical class 0.000 claims description 12
229960000553 somatostatin Drugs 0.000 claims description 12
239000007909 solid dosage form Substances 0.000 claims description 11
239000007788 liquid Substances 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
239000005541 ACE inhibitor Substances 0.000 claims description 9
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 9
239000002461 renin inhibitor Substances 0.000 claims description 9
229940086526 renin-inhibitors Drugs 0.000 claims description 9
238000010521 absorption reaction Methods 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
229930182558 Sterol Natural products 0.000 claims description 2
150000003432 sterols Chemical class 0.000 claims description 2
235000003702 sterols Nutrition 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract description 17
-1 polyoxyethylene Polymers 0.000 abstract description 10
ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 abstract description 8
229940079593 drug Drugs 0.000 abstract description 6
239000003814 drug Substances 0.000 abstract description 6
229920000056 polyoxyethylene ether Polymers 0.000 abstract description 4
229940051841 polyoxyethylene ether Drugs 0.000 abstract description 3
229920000570 polyether Polymers 0.000 description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
238000003127 radioimmunoassay Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000002775 capsule Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
239000000829 suppository Substances 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
239000004721 Polyphenylene oxide Substances 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
241000473945 Theria <moth genus> Species 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
229920001451 polypropylene glycol Polymers 0.000 description 3
150000003839 salts Chemical group 0.000 description 3
239000000243 solution Substances 0.000 description 3
BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
229920002884 Laureth 4 Polymers 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
229940099367 lanolin alcohols Drugs 0.000 description 2
CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
229940058690 lanosterol Drugs 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
229940075620 somatostatin analogue Drugs 0.000 description 2
229940035636 somatostatin and analogues Drugs 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
MUVQIIBPDFTEKM-IUYQGCFVSA-N (2r,3s)-2-aminobutane-1,3-diol Chemical group C[C@H](O)[C@H](N)CO MUVQIIBPDFTEKM-IUYQGCFVSA-N 0.000 description 1
NPJIOCBFOAHEDO-AVWFULIKSA-N (3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](C)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 NPJIOCBFOAHEDO-AVWFULIKSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
NPYXBHZQVNRAOF-UHFFFAOYSA-N 2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]ethanol Chemical compound C1C=C2CC(OCCO)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NPYXBHZQVNRAOF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
206010017788 Gastric haemorrhage Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010022653 Intestinal haemorrhages Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
108700032313 elcatonin Proteins 0.000 description 1
229960000756 elcatonin Drugs 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
229940100556 laureth-23 Drugs 0.000 description 1
229940061515 laureth-4 Drugs 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000000344 soap Substances 0.000 description 1
230000003294 somatostatinlike Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CH2138/86A 1986-05-27 1986-05-27 Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen. CH667994A5 (de)

Priority Applications (28)

Application Number	Priority Date	Filing Date	Title
CH2138/86A CH667994A5 (de)	1986-05-27	1986-05-27	Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen.
HU872150A HU198626B (en)	1986-05-27	1987-05-13	Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
NL8701143A NL8701143A (nl)	1986-05-27	1987-05-13	Farmaceutische preparaten.
DE19873716437 DE3716437A1 (de)	1986-05-27	1987-05-16	Pharmazeutische zusammensetzung
PCT/CH1987/000056 WO1987007149A1 (en)	1986-05-27	1987-05-22	Pharmaceutical compositions
GB8712193A GB2190838B (en)	1986-05-27	1987-05-22	Pharmaceutical compositions
SE8702188A SE8702188L (sv)	1986-05-27	1987-05-25	Farmaceutiska kompositioner
IT8747977A IT1216814B (it)	1986-05-27	1987-05-25	Composizioni farmaceutiche
CA000537928A CA1299495C (en)	1986-05-27	1987-05-25	Pharmaceutical composition containing polypeptide
AU73364/87A AU601740B2 (en)	1986-05-27	1987-05-25	Pharmaceutical compositions
NZ220418A NZ220418A (en)	1986-05-27	1987-05-25	A pharmaceutical composition adapted for g.i. resorption comprising a polypeptide and a monosaccharide or sugar alcohol and/or a polyoxylakylene ether
PT84943A PT84943B (pt)	1986-05-27	1987-05-25	Processo para a preparacao de composicoes farmaceuticas contendo uma mistura de pelo menos, um polipeptido, um monossacarido e um polioxialquileno-eter
GR870820A GR870820B (en)	1986-05-27	1987-05-25	Pharmaceutical compositions
FI872313A FI872313L (fi)	1986-05-27	1987-05-25	Farmaceutiska kompositioner.
BE8700598A BE1000722A4 (fr)	1986-05-27	1987-05-25	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale.
DK265587A DK265587A (da)	1986-05-27	1987-05-25	Farmaceutisk praeparat, der indeholder et polypeptid, til gastro-intestinal resorption
MYPI87000714A MY101233A (en)	1986-05-27	1987-05-25	Pharmaceutical compositions
NO872174A NO171484C (no)	1986-05-27	1987-05-25	Anvendelse av sukkeralkohol, polyoksyalkyleneter eller etmonosakkarid eller blandinger derav som baerer for somatostatiner og kalsitoniner for aa oeke biotilgjengeligheten av peptidene ved oral eller rektal tilfoersel
FR878707368A FR2599254B1 (fr)	1986-05-27	1987-05-25	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale.
IL82645A IL82645A0 (en)	1986-05-27	1987-05-25	Pharmaceutical compositions containing polypeptides
LU86901A LU86901A1 (fr)	1986-05-27	1987-05-26	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale
KR870005303A KR870010870A (ko)	1986-05-27	1987-05-26	약학 조성물의 제조방법
JP62129572A JPS62283930A (ja)	1986-05-27	1987-05-26	医薬組成物
ES8701555A ES2008126A6 (es)	1986-05-27	1987-05-27	Procedimiento para la preparacion de una composicion farmaceutica a base de polipeptidos
ZA873841A ZA873841B (en)	1986-05-27	1987-05-27	Pharmaceutical compositions
CH165/88A CH669909A5 (no)	1986-05-27	1988-05-22
FR8907995A FR2630916B1 (fr)	1986-05-27	1989-06-14	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale
US08/008,383 US5393738A (en)	1986-05-27	1993-01-25	Pharmaceutical compositions containing octreotide and excipients for oral or rectal administration

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH2138/86A CH667994A5 (de)	1986-05-27	1986-05-27	Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen.

Publications (1)

Publication Number	Publication Date
CH667994A5 true CH667994A5 (de)	1988-11-30

Family

ID=4226759

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CH2138/86A CH667994A5 (de)	1986-05-27	1986-05-27	Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen.
CH165/88A CH669909A5 (no)	1986-05-27	1988-05-22

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CH165/88A CH669909A5 (no)	1986-05-27	1988-05-22

Country Status (5)

Country	Link
JP (1)	JPS62283930A (no)
CH (2)	CH667994A5 (no)
IT (1)	IT1216814B (no)
PT (1)	PT84943B (no)
ZA (1)	ZA873841B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007535545A (ja) *	2004-04-28	2007-12-06	プロキャリア・インコーポレーテッド	難吸収性薬剤の経口投与のための製剤
EP2288369B1 (en)	2008-05-07	2014-07-09	Merrion Research III Limited	Compositions of gnrh related compounds and processes of preparation
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en)	2010-03-26	2011-09-29	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP3250191B1 (en)	2015-01-29	2024-01-17	Novo Nordisk A/S	Tablets comprising glp-1 agonist and enteric coating

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57146722A (en) *	1981-03-06	1982-09-10	Toyo Jozo Co Ltd	Pharmaceutical preparation having improved absorption

1986
- 1986-05-27 CH CH2138/86A patent/CH667994A5/de not_active IP Right Cessation
1987
- 1987-05-25 PT PT84943A patent/PT84943B/pt unknown
- 1987-05-25 IT IT8747977A patent/IT1216814B/it active
- 1987-05-26 JP JP62129572A patent/JPS62283930A/ja active Pending
- 1987-05-27 ZA ZA873841A patent/ZA873841B/xx unknown
1988
- 1988-05-22 CH CH165/88A patent/CH669909A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT84943A (en)	1987-06-01
ZA873841B (en)	1989-01-25
IT1216814B (it)	1990-03-14
IT8747977A0 (it)	1987-05-25
JPS62283930A (ja)	1987-12-09
PT84943B (pt)	1990-03-08
CH669909A5 (no)	1989-04-28

Publication	Publication Date	Title
DE69434963T2 (de)	2008-01-17	Selektiv auf die leber wirkende pharmazeutisch aktive substanz
DE60021166T2 (de)	2006-04-27	Neue exendin agonist formulierungen und deren verabreichung
DE60026144T2 (de)	2006-11-16	Benzamidformulierung mit histon-deacetylase-inhibitoraktivität
DE69022678T2 (de)	1996-03-21	S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.
DE3318649A1 (de)	1984-11-22	Zweiphasenformulierung
DE2620446A1 (de)	1977-03-03	Waessriges insulinpraeparat
DE69511539T2 (de)	2000-03-30	Eine cyclosporin enthaltende zubereitung und ein verfahren für ihre herstellung
DE3247786A1 (de)	1983-07-21	Verwendung von peptiden als medikamente
DE3716437A1 (de)	1987-12-03	Pharmazeutische zusammensetzung
DE3537656C2 (no)	1989-03-16
AT396475B (de)	1993-09-27	Säureadditionssalze aus amidiertem taurin oder glycin, deren herstellung und verwendung
WO2001087265A2 (de)	2001-11-22	Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung
DE69508551T2 (de)	1999-09-02	Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
DE69018799T2 (de)	1995-09-21	IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
CH680924A5 (no)	1992-12-15
DE69805096T2 (de)	2002-11-14	Verwendung von ginkgo biloba extrakten zur herstellung eines medikaments
CH667994A5 (de)	1988-11-30	Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen.
EP0277462B1 (de)	1992-04-29	Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin.
CH649562A5 (de)	1985-05-31	Derivate des methionin-enzephalins.
CH683069A5 (de)	1994-01-14	Pharmazeutische Somatostatin-Kompositionen mit verbesserter Resorption, deren Herstellung und Verwendung.
DE69227979T2 (de)	1999-07-01	Modifizierte VIP-Derivate und sie enthaltende pharmazeutische Zusammensetzungen
DE3000139A1 (de)	1981-04-02	Die verwendung von glyzerinphosphorylderivaten in der therapie der dislipaemie, der hepatitis und vergleichgeeignete pharmazeutische kompositionen
EP0021184B1 (de)	1984-02-08	Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
DE69125204T2 (de)	1997-06-26	Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln
DE69525348T2 (de)	2002-09-26	Medikament gegen myotonische dystrophie

Legal Events

Date	Code	Title	Description
1997-05-15	PFA	Name/firm changed	Owner name: SANDOZ AG TRANSFER- NOVARTIS AG
1999-12-31	PL	Patent ceased